<DOC>
	<DOCNO>NCT01864226</DOCNO>
	<brief_summary>This single-center , randomize , investigator/subject-blind , adaptive multiple ascending-dose , placebo-controlled study evaluate safety , tolerability , pharmacokinetics pharmacodynamics RO5545965 healthy volunteer . Subjects randomize receive either RO5545965 match placebo daily 12 day .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics Pharmacodynamics RO5545965 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Adult male female volunteer , 18 64 year age , inclusive Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Body mass index ( BMI ) 18 30 kg/m2 inclusive Female subject must postmenopausal surgically sterile Male subject female partner childbearing potential must use two method contraception , one must barrier method , duration study least 30 day last dose study drug History clinically significant disease disorder Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk subject study Clinically significant abnormality laboratory test result Suspicion regular consumption drug abuse Positive hepatitis B , hepatitis C HIV infection Participation investigational drug device study within 90 day prior screen Regular smoker ( &gt; 5 cigarette , &gt; 1 pipeful &gt; 1 cigar per day ) History clinically significant hypersensitivity allergic drug reaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>